Skip to Main Content Skip to Site Map Skip to Accessibility Statement
Home Formulary 3.0 Respiratory System 3.3 Leukotriene receptor antagonists and phosphodiesterase type-4 inhibitors 3.3.2 Leukotriene receptor antagonists

3.3.2 Leukotriene receptor antagonists

ChoiceDrug
1st choiceMontelukast tablets 10mg

Prescribing Notes

  • Leukotriene receptor antagonists (LTRAs) alone are less effective than inhaled corticosteroids alone or inhaled corticosteroids (ICS) plus long-acting beta-2 agonists (LABAs) in the management of asthma. Montelukast has not been shown to be more effective than a standard dose of inhaled corticosteroid, but the leukotriene receptor antagonists appear to have an additive effect.
  • LRTAs may be of benefit in exercise-induced asthma and in those with concomitant rhinitis, but they are less effective in those with severe asthma who are also receiving high doses of other drugs.
  • If asthma is not controlled on moderate-dose MART despite good adherence, and neither FeNO or eosinophil count is raised, consider a trial of either a LTRA (or a LAMA) in addition to moderate-dose MART. It should be stopped after 8 to 12 weeks if no improvement.
  • Montelukast should be taken at bedtime; those patients that experience sleep disturbance will still get a clinical benefit by switching the dose to the morning.

Cautions

  • Churg-Strauss syndrome has occurred very rarely in association with the use of leukotriene receptor antagonists; in many of the reported cases the reaction followed the reduction or withdrawal of oral corticosteroid therapy. Prescribers should be alert to the development of eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, or peripheral neuropathy.
  • Prescribers should be alert for neuropsychiatric reactions in patients taking montelukast and carefully consider the risks and benefits of continuing treatment if they occur – see MHRA.

 

Also in this Section